Vemurafenib in treating patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic disorders with BRAF V600 Mutations (A Pediatric MATCH Treatment Trial). The gene discussed is BRAF; the disease is non-Hodgkin lymphoma.